Krause und Pachernegg
Verlag für Medizin und Wirtschaft
Artikel   Bilder   Volltext

Mobile Version
A-  |   A  |   A+
Werbung
 
Dia-Präsentation von Merck Gesellschaft mbH.
Micardis(R) - Micardis Plus(R) - Laufende Studien (6 Abbildungen)
Übersicht


Abb. 0: FÜR ÖSTERREICH: Weitere Informationen: Merck Gesellschaft mbH, Zimbagasse 5, 1147 Wien, Tel.: 01/576 00-0 Abb. 1: Laufende Studien Abb. 2: PROTECTION Aktuelles Bild - Abb. 3: ProFESS Abb. 4: Ontarget/Transcend Abb. 5: PROTECTION - Ontarget Abb. 6: Zusammenfassung
Abbildung 3: ProFESS
The PRoFESS(R)study is a randomized, controlled, double-blind study featuring an innovative 2 x 2 factorial design.1 There will be four treatment groups, each enrolling a planned 3875 patients. Each of the primary comparisons will compare patient populations of 7750 patients. The 2 x 2 factorial design provides high power to detect primary end-points. Telmisartan vs placebo. ER-DP + ASA versus clopidogrel. The inclusion criteria are: Ischaemic stroke within 90 days prior to study entry Neurologically and clinically stable Age >55 y Secondary outcomes are: Vascular events (composite of time to first stroke, myocardial infarction, or vascular death) Vascular events or congestive heart failure New onset diabetes 1. The PRoFESS Collaborative Group. Presented at the 30th International Stroke Conference, 2–4 February 2005, New Orleans, Louisiana, USA.
 
ProFESS
Vorheriges Bild Nächstes Bild   


Abbildung 3: ProFESS
The PRoFESS(R)study is a randomized, controlled, double-blind study featuring an innovative 2 x 2 factorial design.1 There will be four treatment groups, each enrolling a planned 3875 patients. Each of the primary comparisons will compare patient populations of 7750 patients. The 2 x 2 factorial design provides high power to detect primary end-points. Telmisartan vs placebo. ER-DP + ASA versus clopidogrel. The inclusion criteria are: Ischaemic stroke within 90 days prior to study entry Neurologically and clinically stable Age >55 y Secondary outcomes are: Vascular events (composite of time to first stroke, myocardial infarction, or vascular death) Vascular events or congestive heart failure New onset diabetes 1. The PRoFESS Collaborative Group. Presented at the 30th International Stroke Conference, 2–4 February 2005, New Orleans, Louisiana, USA.
 
copyright © 2003–2017 Krause & Pachernegg GmbH | Sitemap | Impressum
 
Werbung